New COVID-19 antigens and diagnostic kits now available for collaborators

FEATURED COVID-19 PRODUCTS

COVID Antigens

Recombinant SARS-CoV-2 Nucleocapsid and Spike Protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology

COVID Antigen Array

Contains full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS
and MERS

COVID Microtitre Plate

Contains full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS
and MERS

What We Do

What We Do

  • Identify drug responders with >90% accuracy

  • Use our antigens to develop better vaccines and diagnostic tests

  • Diagnose cancer & autoimmune diseases 5 to 7 years earlier

  • Identify drug responders with >90% accuracy

  • Diagnose cancer & autoimmune diseases 5 to 7 years earlier

  • Use our antigens to develop better vaccines and diagnostic tests

Sengenics measures autoantibodies at unrivalled sensitivity and specificity

UPCOMING EVENTS

APRIL 24 – 29, 2020

KREX TECHNOLOGY

KREX™ utilises the BCCP folding marker to actively select for soluble, correctly folded, functional proteins

PARTNERING

Engage in innovative research, discovery and development through active long-term collaborations with us

DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X